Many Cord Blood Companies Experiencing Double Digit Growth

A report called 'Capitalizing on Opportunities in Cord Blood Industry Growth' was just released by MarketResearch.com, which describes how a certain sector of blood banks are experiencing a very fast growth rate, ranging from 17% per year to 25% per year. The 201 page report is available for download for $3,995. This industry has got the attention of billionaires, such as Richard Branson, of Virgin Records and Virgin Atlantic Airways fame. He created Virgin Health, a cord blood bank.

So what is cord blood? Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Cord blood of a baby is preserved in the event it may be needed at some point in the future for treatment of the cancer or genetic disease of the child or the child's siblings. Many diseases have been treated with cord blood. Information on cord blood and how it is collected, stored, and used, is available at CordBloodStocks.com.

Investors have two options when investing in this industry. They can own the stocks of the cord blood banks or own the companies that use cord blood to develop cures and produce extraction and storage products. One that falls into the second category is PerkinElmer, Inc. (PKI), which owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 10 times forward earnings and pays a decent yield of 1.5%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a forward price to earnings ratio of 10 and sports a yield of 2.7%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The stock has a forward PE of 14.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 10 and carries a yield of 2.0%.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services. The company is based in Beijing, China. The stock trades at 9 times earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

U of Colorado Opens Cord Blood Bank: What About Cord Blood Stocks

University of Colorado recently opened a public cord blood bank, funded by the federal government. Donations are accepted from almost anyone and the cord blood is available to those in need.

Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks, both private and public, are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Parents often have their baby's cord blood preserved in the event it may be needed at some point in the future for treatment of their child's or the child's sibling's cancer or genetic disease. Numerous diseases have been treated with cord blood. For a lot more detail on cord blood and how it is collected, stored, and used, go to CordBloodStocks.com.

The cord blood industry continues to grow. Even Richard Branson, of Virgin Records and Virgin Atlantic Airways fame, set up Virgin Health, a cord blood bank. Investors have a two-pronged approach to this investment industry: owning the stocks of the cord blood banks or owning the companies that use cord blood to develop cures.

PerkinElmer, Inc. (PKI) owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 12 times forward earnings and pays a yield of 1.3%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a forward price to earnings ratio of 12 and pays a yield of 2.3%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The forward PE is 14, but does not pay a dividend.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 10 and sports a yield of 2.1%.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services. The company is based in Beijing, China. The stock does not pay a dividend but trades at 12 times earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Top Cord Blood Stocks

The University of South Florida Department of Neurosurgery and Brain Repair just published the results of their research showing that after stroke-like damage, human umbilical cord blood cells protect astrocytes (animal cells) from cell death when deprived of oxygen.

Cord blood is blood that comes from umbilical cords, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Parents often have their newborn's cord blood preserved in the event it may be needed at some point in the future for treatment of their child's or the child's sibling's cancer or genetic disease. Numerous diseases have been treated with cord blood. For a lot more detail on cord blood and how it is collected, stored, and used, go to CordBloodStocks.com.

The cord blood industry is a fast growing industry, and includes the likes of Richard Branson, of Virgin Records and Virgin Atlantic Airways fame, who set up Virgin Health, a cord blood bank.

Investors have the option of owning the cord blood banks or the companies that use cord blood to develop cures (or both). Here are some stocks that participate in the cord blood business. Be aware that some of these companies have low market caps and are very speculative.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a PE ratio of 17 and pays a yield of 2.6%.

PerkinElmer, Inc. (PKI) owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock has a PE of 19 and a yield of 1.4%.

Celgene (CELG) This New Jersey company is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The P/E is 27.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a PE of 11.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services.The company is based in Beijing, China. The stock has a PE of 40 and a forward PE of 20.

The following stocks are extremely low cap stock and should therefore be considered extremely speculative.

Cryo-Cell International (CCEL.OB) This is a Florida based cord blood stem cell bank, specializing in the family market. The stock has a PE ratio of 10.

ThermoGenesis (KOOL) This California company designs, makes, and sells automated blood processing systems for the manufacture, preservation, and delivery of cell therapies. They are involved in a joint venture with GE Healthcare, a unit of General Electric Company (GE) to distribute the AXP[TM] AutoXpress Platform, a closed and automated system for harvesting mononuclear cells from cord blood. They have recently generated negative earnings.

Cord Blood America Inc. (CBAI.OB) One of the cord blood bankers, this Los Angeles company is involved in the collection, testing, processing, and preservation of the blood from umbilical cords for use in future stem cell therapy. They own the Cord Partners umbilical cord blood banking company. They have recently generated negative earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded and sorted, go to WallStreetNewsNetwork.com.

Author does not own any of the above.

By Stockerblog.com

Another Cord Blood Stock

A couple weeks ago, we had an article about cord blood stocks. However, they are all United States companies. There is one more that should be added to the list, China Cord Blood Corporation (CO), which trades on the New York Stock Exchange.

It provides cord blood collection, and stem cell storage services.The company, which is based in Beijing, China, reported a 30.4% increase in revenues for the latest reported quarter, ending September, and a 205% increase in earnings.

To see more Cord Blood companies, check out cord blood stocks.